Cardiovascular and neuropsychiatric safety of smoking cessation pharmacotherapies in non-depressed adults: a retrospective cohort study.

BACKGROUND AND AIMS Pharmacotherapies for smoking cessation are widely prescribed, despite substantial concerns being raised regarding the potential increased risk of cardiovascular (CV) and neuropsychiatric adverse events associated with these treatments. This study aimed to assess the relative CV and neuropsychiatric safety between varenicline and bupropion compared with nicotine replacement therapies (NRT) in adults without a recent history of depression. DESIGN Retrospective new-user cohort study. SETTING US administrative data from 2006 to 2016 covering more than 100 million individuals. PARTICIPANTS Three study cohorts of new users, aged 18 years or older, limited to patients with no diagnosis or treatment for depression in the prior 12 months. MEASUREMENTS Propensity score adjusted log-binomial regression models. The primary outcome was a composite of hospitalized CV events. Secondary outcomes included a composite of hospitalized neuropsychiatric events and individual components of the primary outcome. FINDINGS A total of 618 497 participants were included in our study cohorts. Compared with NRT (n = 32 237), varenicline (n = 454 698) was associated with a 20% lower 1-year CV risk [adjusted relative risk (RR) = 0.80, 95% confidence interval (CI) = 0.75-0.85], and bupropion (n = 131 562) was associated with a 25% lower 1-year CV risk (RR = 0.75, 95% CI = 0.69-0.81). Varenicline was associated with a 35% lower 1-year risk of neuropsychiatric hospitalization versus NRT (RR = 0.65, 95% CI = 0.59-0.72), and bupropion was associated with a 21% increase in 1-year risk of neuropsychiatric hospitalization (RR = 1.21, 95% CI = 1.09-1.35). CONCLUSION Varenicline compared with nicotine replacement therapy does not appear to be associated with an increased risk of cardiovascular or neuropsychiatric hospitalizations. Bupropion appears to be associated with a lower risk of cardiovascular hospitalization and a higher risk of neuropsychiatric hospitalization, compared with nicotine replacement therapy.

[1]  Yumi Motooka,et al.  Adverse events of smoking cessation treatments (nicotine replacement therapy and non-nicotine prescription medication) and electronic cigarettes in the Food and Drug Administration Adverse Event Reporting System, 2004−2016 , 2018, SAGE open medicine.

[2]  S. Tonstad,et al.  Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial , 2018, JAMA internal medicine.

[3]  M. Munafo,et al.  The effects of prescribing varenicline on two‐year health outcomes: an observational cohort study using electronic medical records , 2018, Addiction.

[4]  E. Claus,et al.  Moderators of smoking cessation outcomes in a randomized-controlled trial of varenicline versus placebo , 2017, Psychopharmacology.

[5]  Donald R. Miller,et al.  A comparison of neuropsychiatric adverse events during early treatment with varenicline or a nicotine patch. , 2016, Addiction.

[6]  N. Benowitz,et al.  Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial , 2016, The Lancet.

[7]  K. Filion,et al.  Varenicline and Adverse Cardiovascular Events: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials , 2016, Journal of the American Heart Association.

[8]  M. Munafo,et al.  Cardiovascular and neuropsychiatric risks of varenicline: too good to be true? , 2015, The Lancet. Respiratory medicine.

[9]  Brian A. King,et al.  Current Cigarette Smoking Among Adults — United States, 2016 , 2015, MMWR. Morbidity and mortality weekly report.

[10]  Colin Simpson,et al.  Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study , 2015, The Lancet. Respiratory medicine.

[11]  P. Lichtenstein,et al.  Varenicline and risk of psychiatric conditions, suicidal behaviour, criminal offending, and transport accidents and offences: population based cohort study , 2015, BMJ : British Medical Journal.

[12]  M. Saladin,et al.  An exploratory short-term double-blind randomized trial of varenicline versus nicotine patch for smoking cessation in women. , 2015, Addiction.

[13]  J. Higgins,et al.  Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis , 2015, BMJ : British Medical Journal.

[14]  S. Rennard,et al.  Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. , 2015, JAMA.

[15]  Diane Lacaille,et al.  Validity of Myocardial Infarction Diagnoses in Administrative Databases: A Systematic Review , 2014, PloS one.

[16]  K. Zou,et al.  Effect of varenicline on individual nicotine withdrawal symptoms: a combined analysis of eight randomized, placebo-controlled trials. , 2013, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[17]  F. Windmeijer,et al.  Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study , 2013, BMJ.

[18]  C. Yunis,et al.  Effects of Varenicline on Smoking Cessation in Adults With Stably Treated Current or Past Major Depression , 2013, Annals of Internal Medicine.

[19]  J. B. Layton,et al.  Propensity Score Methods for Confounding Control in Nonexperimental Research , 2013, Circulation. Cardiovascular quality and outcomes.

[20]  H. Svanström,et al.  Use of varenicline versus bupropion and risk of psychiatric adverse events. , 2013, Addiction.

[21]  R. Perera,et al.  Pharmacological interventions for smoking cessation: an overview and network meta-analysis. , 2013, The Cochrane database of systematic reviews.

[22]  Jeffrey M. Engelmann,et al.  Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. , 2013, JAMA psychiatry.

[23]  Prabhat Jha,et al.  21st-century hazards of smoking and benefits of cessation in the United States. , 2013, The New England journal of medicine.

[24]  H. Svanström,et al.  Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study , 2012, BMJ : British Medical Journal.

[25]  Thomas R Fanshawe,et al.  Combined pharmacotherapy and behavioural interventions for smoking cessation. , 2016, The Cochrane database of systematic reviews.

[26]  Mark Olfson,et al.  A systematic review of validated methods for identifying suicide or suicidal ideation using administrative or claims data , 2012, Pharmacoepidemiology and drug safety.

[27]  Curt D. Furberg,et al.  Suicidal Behavior and Depression in Smoking Cessation Treatments , 2011, PloS one.

[28]  Kenneth W Lin,et al.  Nicotine receptor partial agonists for smoking cessation. , 2011, American family physician.

[29]  H. Riordan,et al.  A Double-Blind Randomized Placebo-Controlled Pilot Study of Neuropsychiatric Adverse Events in Abstinent Smokers Treated with Varenicline or Placebo , 2011, Biological Psychiatry.

[30]  S. Rennard,et al.  Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. , 2011, Chest.

[31]  K. Fagerström,et al.  Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial , 2010, BMJ : British Medical Journal.

[32]  D. Gunnell,et al.  Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database , 2009, BMJ : British Medical Journal.

[33]  J. Avorn,et al.  High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data , 2009, Epidemiology.

[34]  J. Britton,et al.  Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial , 2008, Thorax.

[35]  T. Ishibashi,et al.  Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. , 2007, Clinical therapeutics.

[36]  C. Weinberg,et al.  Long-term fatty fish consumption and renal cell carcinoma incidence in women. , 2006, JAMA.

[37]  Jason Gong,et al.  Efficacy of Varenicline, an 42 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation A Randomized Controlled Trial , 2006 .

[38]  David Gonzales,et al.  Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial , 2006 .

[39]  M. Damaj,et al.  Bupropion is a nicotinic antagonist. , 2000, The Journal of pharmacology and experimental therapeutics.

[40]  Donald Rubin,et al.  Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.

[41]  Tamra E. Meyer,et al.  Neuropsychiatric events in varenicline and nicotine replacement patch users in the Military Health System. , 2013, Addiction.

[42]  Stephen M. Stahl,et al.  A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. , 2004, Primary care companion to the Journal of clinical psychiatry.

[43]  Colin Simpson,et al.  Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease , 2017, Thorax.